Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis.1992;14:773-779.
Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis
C virus infections. Clin Infect Dis.1996;23:1117-1125.
Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the
development of the hepatitis B virus carrier state. J Infect Dis.1991;163:1138-1140.
Perrillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to
the human immunodeficiency virus. Ann Intern Med.1986;105:382-383.
Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet.1997;349:924-925.
Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with
Arribas JR, Ibanez C, Ruiz-Antoran B.
et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS.1998;12:1722-1724.
Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS.1998;12:1256.
Markowitz M, Conant M, Hurley A.
et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human
immunodeficiency (HIV)-1 protease, to treat HIV infection. J Infect Dis.1998;177:1533-1540.
Lee C, Stein JJ, Kravetz JD.
et al. Hepatic complications of HIV-infected individuals treated with indinavir. J Acquir Immune Defic Syndr.In press.
Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of
adverse events: the nonsteroidal anti-inflammatory drug story. Arch Intern Med.1997;157:2129-2136.
Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med.1996;101:34-40.
Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial difference in the use of drug therapy for HIV disease in an
urban community. N Engl J Med.1994;330:763-768.
AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, Md: Division of AIDS, National Institute of Allergy and
Infectious Diseases; 1996.
Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. MMWR Morb Mortal Wkly Rep.1998;47(RR-3):38-78.
Hammer SM, Katzenstein DA, Hughes MD.
et al. A trial comparing nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med.1996;335:1081-1090.
The Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations
of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected
Randomised trial of addition of lamivudine or lamivudine plus loviride
to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR
Indinavir sulfate (Crixivan) [package insert]. West Point, Pa: Merck & Co Inc; 1997.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Nelfinavir mesylate (Viracept) [package insert]. La Jolla, Calif: Agouron Pharmaceuticals Inc; 1997.
Delmas C, Szafir D, Trylesinski A.
et al. Safety profile of Viracept in the treatment of HIV patients: the French
compassionate use program experience. In: Abstracts from the 12th World AIDS Conference; June 28-30 and
July 1-2, 1998; Geneva, Switzerland. Abstract 12393.
Saquinavir mesylate (Invirase) [package insert]. Nutley, NJ: Roche Laboratories Inc; 1997.
Saquinavir soft gelatin capsules (Fortavase) [package insert]. Nutley, NJ: Roche Laboratories Inc; 1997.
Collier AC, Coombs RW, Schoenfeld DA.
et al. Treatment of human immunodeficiency virus infection with saquinavir,
zidovudine, and zalcitabine. N Engl J Med.1996;334:1011-1018.
Gill MJ. Safety profile of soft gelatin formulation of saquinavir in combination
with nucleosides in a broad patient population. AIDS.1998;12:1400-1402.
Ritonavir (Norvir) [package insert]. Abbott Park, Ill: Abbott Laboratories; 1997.
Cameron DW, Heath-Chiozzi M, Danner S.
et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1
Danner SA, Carr A, Leonard JM.
et al. A short-term study of the safety, pharmacokinetics, and efficacy of
ritonavir, an inhibitor of HIV-1 protease. N Engl J Med.1995;333:1528-1533.
Markowitz M, Saag M, Powderly WG.
et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to
treat HIV-1 infection. N Engl J Med.1995;333:1534-1539.
Cameron DW, Japour A, Mellors J.
et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease
inhibitor naïve patients in year two of follow-up. In: Programs and abstracts of the 5th Conference on Retroviruses
and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 388.
Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor
ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther.1996;277:423-431.
Carr A, Samaras K, Burton S.
et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin
resistance in patients receiving HIV protease inhibitors. AIDS.1998;12:F51-F58.
Ungo JR, Jones D, Ashkin D.
et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis
C virus and the human immunodeficiency virus. Am J Respir Crit Care Med.1998;157:1871-1876.
Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease
inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis.1998;177:783-785.
Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected
patients on antiretroviral combination therapy. AIDS.1998;12:116-117.
John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected
patients with HIV protease inhibitors: an immune restoration disease? AIDS.1998;12:2289-2293.
Verdon R, Vabret A, Goubin P.
et al. HIV-HCV coinfection: is HIV viral load decrease associated with HCV
viral load variations. In: Abstracts of the 38th Interscience Conference on Antimicrobial
Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract
Zylberberg H, Chaix M-L, Rabian C.
et al. Tritherapy for human immunodeficiency virus infection does not modify
replication of hepatitis C virus in coinfected subjects. Clin Infect Dis.1998;26:1104-1106.
Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA.1997;278:63-65.
Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus
disease. N Engl J Med.1995;333:751-756.
Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk
factors for virologic failure and adverse drug reactions. Ann Intern Med.1999;131:81-87.
Thomas DL, Rai R, Anania F.
et al. A prospective investigation of hepatitis C viral load [abstract]. Hepatology.1998;28:568.